Log in to search using one of your social media accounts:

 

Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news

New Evidence Points to Benefits of Zoledronic Acid for Advanced...
The bisphosphonate may be an option for mesothelioma patients who are not benefitting from other treatments.(PRWeb July 01, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14478826.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 1, 2017 Category: Pharmaceuticals Source Type: news

Denosumab Shows Benefits in Multiple Myeloma Bone Disease Denosumab Shows Benefits in Multiple Myeloma Bone Disease
In a head-to-head comparison with zoledronic acid, denosumab was noninferior, with prolonged time to a first skeletal event and a reduced risk for renal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid Data Selected for Best of ASCO® Educational Program THOUSAND OAKS, Calif., June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The ...
Source: Amgen News Release - June 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Mylan Launches Generic Reclast(R) Injection
HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis' Recl... Biopharmaceuticals, Generics, FDA, Product Launch Mylan, Zoledronic Acid, Reclast, Paget's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 2, 2017 Category: Pharmaceuticals Source Type: news

Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO® First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented THOUSAND OAKS, Calif., May 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd An...
Source: Amgen News Release - May 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

ACP Updates Guidelines on Treating Low Bone Density, Osteoporosis (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Clinicians should offer alendronate, risedronate, zoledronic acid, or denosumab to women with osteoporosis to reduce the risk for hip and vertebral fractures (strong … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 9, 2017 Category: Primary Care Source Type: news

Guideline for treating low bone density or osteoporosis to prevent fractures
The American College of Physicians recommends in an evidence-based clinical practice guideline that physicians treat women with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 8, 2017 Category: Science Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.... (Source: Amgen News Release)
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma ...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New clinical trial to test drug combination to treat osteogenesis imperfecta
The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2017 Category: Pharmaceuticals Source Type: news

Reducing Zoledronic Acid Frequency Did Not Raise Risk of Skeletal Events
Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks. (Source: CancerNetwork)
Source: CancerNetwork - January 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bone Metastases Breast Cancer Multiple Myeloma News Prostate Cancer Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report Source: HealthDay Related MedlinePlus Pages: Bone Cancer, Breast Cancer, Prostate Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 4, 2017 Category: Consumer Health News Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
WEDNESDAY, Jan. 4, 2017 -- Use of a bone cancer drug once every three months, instead of monthly, does not boost the risk of bone problems over two years, a new study finds. That could reduce side effects from the drug, known as zoledronic acid... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 4, 2017 Category: Journals (General) Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - January 4, 2017 Category: Cancer & Oncology Source Type: news

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 3, 2017 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Oncology, Pharmacy, Rheumatology, News, Source Type: news

Longer Dosing Interval for Zoledronic Acid for Bone Mets Longer Dosing Interval for Zoledronic Acid for Bone Mets
Increasing the dosing interval of zoledronic acid did not cause an increase in skeletal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Docetaxel, zoledronic acid not cost  effective for prostate cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2016 Category: Drugs & Pharmacology Source Type: news

Non-TCA/SSRI Antidepressants Increase Fall Risk in Elderly Frail Women
Antidepressants from classes other than tricyclics (TCAs) and selective serotonin reuptake inhibitors (SSRIs) did not appear to reduce the risk for falls, according to results of the Zoledronic acid in frail Elders to STrengthen bone (ZEST) study. (Source: Caring for the Ages)
Source: Caring for the Ages - September 29, 2016 Category: Health Management Authors: Jason Harris Source Type: news

Make the Diagnosis: Bewildering Bone Pain
(MedPage Today) -- Case Findings: A 23-year-old male presents with a presumed diagnosis of vanishing bone disease (Gorham's disease), a rare condition in which bone is lost in conjunction with an overgrowth of lymphatic vessels. However, the patient presents with ongoing severe pain, which is uncommon in Gorham's disease. He was treated with interferon and zoledronic acid, but discontinued these treatments because of severe side effects. What is your diagnosis? (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 26, 2016 Category: Cardiology Source Type: news

Reclast (zoledronic acid)
Title: Reclast (zoledronic acid)Category: MedicationsCreated: 1/3/2008 12:00:00 AMLast Editorial Review: 9/13/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 13, 2016 Category: Rheumatology Source Type: news

Osteoporosis Treatment Alternatives To Bisphosphonates
Big Pharma employs a lot of very serious spin-doctors. I’ll give you a good example. Bisphosphonates For Osteoporosis? A new study just came out on bisphosphonate drugs. These are the most commonly prescribed drugs for osteoporosis. They’re worth about $8.5 billion per year to the drug companies. But this new study says that one-third of the women taking these drugs are still at high risk for fractures.  Now here’s what you have to understand. The study was done by a subsidiary of Merck & Co. They make Fosamax, one of the biggest bone drugs. So instead of saying the drugs don’t work ...
Source: Al Sears, MD Natural Remedies - September 6, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Health Source Type: news

Zoledronic acid protects against bone density loss caused by antiretrovirals
Administering 5 mg of zoledronic acid at the start of antiretroviral therapy to HIV-infected patients who have never previously undergone ART can significantly decrease the risk of bone density loss.... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 30, 2016 Category: Endocrinology Source Type: news

Progeria triple-therapy findings ‘disappointing’
Pravastatin and zoledronic acid provide no additional clinically relevant benefit to lonafarnib monotherapy for patients with Hutchinson-Gilford progeria syndrome, study findings indicate. (Source: MedWire News)
Source: MedWire News - July 12, 2016 Category: Consumer Health News Tags: Cardiology Source Type: news

Single-Dose Drug Decreases Bone Loss in Newly Treated HIVSingle-Dose Drug Decreases Bone Loss in Newly Treated HIV
A single dose of zoledronic acid given at the start of ART decreases bone loss over the course of 48 weeks in HIV, according to a small, single-center, proof-of-concept study. Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 23, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Zoledronic acid improved bone health in patients with osteoporosis
Use of zoledronic acid for the treatment of osteoporosis enhanced bone mineral density and reduced bone turnover in patients, according to results published in the journal Orthopedics. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 4, 2016 Category: Endocrinology Source Type: news

Zometa (Zoledronic Acid for Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2016 Category: Drugs & Pharmacology Source Type: news

Reclast (Zoledronic Acid Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 25, 2016 Category: Drugs & Pharmacology Source Type: news

Zolodrenic acid can prevent early bone loss in HIV patients on antiretroviral therapy
(Emory Health Sciences) A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy. Bone loss also leads to a higher rate of fracture in HIV-infected individuals. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2016 Category: Global & Universal Source Type: news

Adverse events after paediatric zoledronic acid infusion common
Although acute adverse events associated with zoledronic acid infusion in paediatric patients with bone disorders are common, they mainly occur after the initial infusion and are generally mild and easily managed, according to recent findings published in the Journal of Clinical Endocrinology and Metabolism. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 14, 2015 Category: Endocrinology Source Type: news

Complications of New MedicationsComplications of New Medications
This case of jaw osteonecrosis highlights a potential adverse effect of zoledronic acid, commonly prescribed for osteoporosis. Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2015 Category: Consumer Health News Tags: Emergency Medicine Journal Article Source Type: news

Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial - Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM.
IMPORTANCE: Eighty-five percent of institutionalized elderly people have osteoporosis and bone fracture rates 8 to 9 times higher than rates observed among community-dwelling elderly people. Nevertheless, most of these persons are left untreated and are ex... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 17, 2015 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Zoledronic Acid Ups BMD in Seniors Without Cutting FracturesZoledronic Acid Ups BMD in Seniors Without Cutting Fractures
A single infusion of zoledronic acid improved BMD over the course of 2 years in frail institutionalized elderly women with osteoporosis, but this improvement did not translate to better outcomes. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2015 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Zoledronic Acid Improves Bone Density in Frail Elders with Osteoporosis (FREE)
By Jenni Whalen Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Frail older women with osteoporosis may benefit from one dose of zoledronic acid (Reclast) during a 2-year period, according to a study in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 14, 2015 Category: Primary Care Source Type: news

Bone mineral density improved in frail elderly women treated with zoledronic acid
A single intravenous dose of the osteoporosis drug zoledronic acid improved bone mineral density in a group of frail elderly women living in nursing homes and long-term-care facilities. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 13, 2015 Category: Science Source Type: news

EU Advisory Body Aims to Reduce Bone Drug Osteonecrosis Risk EU Advisory Body Aims to Reduce Bone Drug Osteonecrosis Risk
The European Medicines Agency's pharmacovigilance panel advises new product labeling and patient reminders about the osteonecrosis risk with zoledronic acid, with future plans to target other bone drugs. News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Reclast May Protect Bone by Reversing Marrow Fat
(MedPage Today) -- Early zoledronic acid reverses bone marrow adipogenesis during estrogen deficiency. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 7, 2015 Category: Endocrinology Source Type: news

Disseminated prostate cancer cells in bone
Most castrate-resistant prostate cancer patients develop bone metastases, and standard androgen deprivation therapy causes bone loss. Whether this treatment-induced bone microenvironment change affects disseminated tumour cells, thereby stimulating bone metastasis development, is not known. Ottewell and colleagues used an in vivo model to mimic androgen ablation, finding increased bone resorption and loss of bone volume, compared with controls. In addition, the growth and metastasis  of disseminated tumour cells was triggered. Weekly administration of zoledronic acid prevented this tumour growth, but did not elimi...
Source: Society for Endocrinology - October 21, 2014 Category: Endocrinology Source Type: news

Who Needs Zoledronic Acid in Early Breast Cancer?Who Needs Zoledronic Acid in Early Breast Cancer?
Dr. Lidia Schapira describes the role of adjuvant bisphosphonates in early breast cancer as unclear, but suggests that host factors may prove key to efficacy. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Prostate Cancer and Zoledronic Acid: Two Emerging PatternsProstate Cancer and Zoledronic Acid: Two Emerging Patterns
The phase 3 RADAR trial looking at zoledronic acid in prostate cancer suggests 2 emerging standards of care, depending on Gleason score. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bisphosphonates Not Associated with Reduced Breast Cancer Risk (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The bisphosphonates alendronate and zoledronic acid do not reduce the risk for breast cancer among postmenopausal women, according to findings from two randomized trials … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 11, 2014 Category: Primary Care Source Type: news

ASCO: OK to Cut Back on Bone Mets Therapy
CHICAGO (MedPage Today) -- Less frequent dosing of zoledronic acid (Zometa) after the first year in breast cancer metastatic to the bone was just as good for preventing skeletal events with potentially less toxicity, a trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 31, 2014 Category: Hematology Source Type: news

Breast Cancer With Bone Mets: Less Zoledronic Acid Is FineBreast Cancer With Bone Mets: Less Zoledronic Acid Is Fine
Women with breast cancer and bone metastasis can scale back on the use of a bone-building drug over time and apparently still get the same benefit, new research suggests. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 30, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without compromising care
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 30, 2014 Category: Science Source Type: news

Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without comp
(University of Texas M. D. Anderson Cancer Center) Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2014 Category: Cancer & Oncology Source Type: news